Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ZL-1109

Other · developed by Zai Lab Co.

Phase 3 Most advanced trial
ZLAB Developer
1 Registered trials

What is ZL-1109?

ZL-1109 is a subcutaneously injected agent studied in thyroid eye disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Ophthalmology
Developer
Zai Lab Co., Ltd. (ZLAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07211776 Phase 3 Thyroid Eye Disease (TED) Active not recruiting ZLAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Thyroid Eye Disease (TED)

More from Zai Lab Co.

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the ZLAB page.

Follow ZLAB, the company behind ZL-1109

See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZLAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.